Assessment of early strut coverage after COMBO and Everolimus eluting stent using optical coherence tomography astudy

Assessment of early strut coverage after COMBO and Everolimus eluting stent using optical coherence tomography astudy - Assessment of early strut coverage after COMBO and Everolimus eluting stent (COMMENT trial)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000044239

Enrollment

Registered

2021-05-18

Start date

2021-03-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Heart Disease

Interventions

Patients were randomly assigned to receive either the COMBO stent or everolimus eluting stent. One month later, we investigate the strut coverage using OCT.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with two vessel disease who are planned to undergo percutaneous coronary intervention

Exclusion criteria

Exclusion criteria: Patients with serum creatinine > 2.0mg/dl

Design outcomes

Primary

Measure	Time frame
strut coverage	—

Countries

Japan

Contacts

Public ContactTakatoshi Wakeyama

Japan Community Healthcare Organization Tokuyama Central Hospital Division of Cardiology

wakeyama@icloud.com+81-834-28-4411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026